Market Overview

Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2


The J.P. Morgan Healthcare Conference is from January 12 to 15. This healthcare conference is one of the largest and most important conferences for biotech companies all year.

January 13 is Day Two for the conference and a number of biotech companies will make presentations. Some of these companies will also have question and answer sessions after their presentation.

Here are some key times that select biotech companies are presenting on Tuesday. The conference is in San Francisco; all times are in Pacific Standard Time.

7:30 AM: Alkermes Plc (NASDAQ: ALKS)

8:00 AM: Orexigen Therapeutics, Inc. (NASDAQ: OREX)

8:30 AM: Gilead Sciences, Inc. (NASDAQ: GILD)

9:00 AM: ImmunoGen, Inc. (NASDAQ: IMGN), Express Scripts Holding Company (NASDAQ: ESRX), Bristol-Myers Squibb Co (NYSE: BMY), Boston Scientific Corporation (NYSE: BSX)

9:30 AM: Amgen, Inc. (NASDAQ: AMGN)

10:00 AM: Ultragenyx Pharmaceutical Inc (NASDAQ: RARE)

10:30 AM: Regeneron Pharmaceuticals Inc (NASDAQ: REGN), Amicus Therapeutics, Inc. (NASDAQ: FOLD), Catalent Inc (NYSE: CTLT)

11:00 AM: Nektar Therapeutics (NASDAQ: NKTR)

11:30 AM: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Eli Lilly and Co (NYSE: LLY)

2:30 PM: ZS Pharma Inc (NASDAQ: ZSPH), Pfizer Inc. (NYSE: PFE), Karyopharm Therapeutics Inc (NASDAQ: KPTI)

3:00 PM: Otonomy Inc (NASDAQ: OTIC)

3:30 PM: NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Accelerate Diagnostics Inc (NASDAQ: AXDX)

4:00 PM: Keryx Biopharmaceuticals (NASDAQ: KERX), Halozyme Therapeutics, Inc. (NASDAQ: HALO), GlaxoSmithKline plc (ADR) (NYSE: GSK), Opko Health Inc. (NYSE: OPK)

Two companies in the headlines that are scheduled to present on Tuesday are NPS Pharmaceuticals and Bristol-Myers Squibb. Last weekend, Shire PLC (ADR) (NASDAQ: SHPG) announced it will acquire NPS for $5.2 billion, or $46 a share.

This was about a 10 percent premium to the previous week's close, but a significant premium over the average price of the last 45 trading sessions.

Related Link: JP Morgan Healthcare Conference: Day 1 Preview

Bristol-Myers Squibb announced that its drug, Opdivo, prolonged survival in patients with lung cancer. The study was stopped early because the study met endpoints before it was expected to. 


Related Articles (ALKS + OREX)

View Comments and Join the Discussion!

Posted-In: JP Morgan Healthcare ConferenceNews Previews FDA Trading Ideas